Navigation Links
St. Jude Children's Research Hospital names James R. Downing, M.D., CEO

Downing, internationally recognized as a genome sequencing pioneer and member of the National Academy of Sciences' Institute of Medicine, becomes sixth leader to serve at hospital's helm

(MEMPHIS, Tenn. June 25, 2014) St. Jude Children's Research Hospital,, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing's primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his longstanding pharmacogenomics research program at St. Jude.

Downing's work as a genome sequencing pioneer, overseeing the Pediatric Cancer Genome Project, was recognized in 2012 by TIME Magazine as one of the Top 100 new scientific discoveries. "Dr. Downing is an exceptional scientist whose visionary approach to the next era of growth and discovery at St. Jude will mirror the legacy established by Danny Thomas more than 50 years ago," said Terry Burman, chairman of the St. Jude Board of Governors. "Dr. Downing's seminal contributions to understanding genetic origins of disease, as both the catalyst and leader of the St. Jude Pediatric Cancer Genome Project initiatives, have laid a foundation for a new period of research and treatment of childhood cancer and other life-threatening diseases."

"It is my responsibility as the new CEO of St. Jude to ensure that St. Jude remains the global leader in the fight against pediatric cancer and other deadly illnesses, continuing to set the global agenda to achieve our mission to advance cures," Downing said. "Today's intersection of science and technology is paving the way for unprecedented discovery and innovative treatment. I am honored to lead an institution that values collaboration and daring, forward-thinking investigation; an institution where the translational goal of our research makes it impossible to separate research from patient care; an organization that provides unsurpassed care for today as we work to identify the next advances and improve cure rates for tomorrow."

Taking the reins of the institution that is home to the only NIH/NCI Comprehensive Cancer Center devoted solely to children, Downing outlined his vision for St. Jude's next generation of clinical and research expansion, inspired by the responsibility of leading a global enterprise that is nearly 75 percent funded by the general public. This will include:

  • Continuing growth in the number of cancer patients treated on the St. Jude campus;
  • Expansion of the institution's treatment and research program on pediatric solid tumors, to address the plateau of global progress over the last decade where new efforts are desperately needed;
  • A significant expansion of St. Jude's International Outreach Program, a global effort that is focused on teaching practitioners in developing countries how to effectively treat children with cancer, as well as the global expansion of St. Jude-led treatment studies;
  • Through the Pediatric Cancer Genome Project, St. Jude will incorporate an unprecedented level of comprehensive genomic analyses into the clinical work-up of every child treated;
  • Growth in the number of patients enrolled on the St. Jude Life long-term follow-up survivor study, a program that is helping to define the long-term health problems of survivors of pediatric cancer and determine how to effectively manage and ultimately eliminate these medical problems;
  • Establish a formalized patient advocacy consortium, in partnership with existing organizations, to better serve the patient-family community, including acceleration of federal and private drug therapy development and approvals.

"There is no institution in the world like St. Jude., so it is not surprising that following an extensive global search, the St. Jude Board of Governors found the most qualified and best prepared person here at St. Jude Dr. Jim Downing," said Dr. Evans. "Jim is inheriting a 52-year legacy of unparalleled medical discovery and innovative clinical trials that take on the toughest cases, all made possible by unwavering public support of donors and partners from around the world. Jim and I have worked very closely for the last decade, and I know he will do an extraordinary job as my successor."

"Dr. Downing is truly a visionary scientific and medical leader who has dedicated much of his professional life to St. Jude," said Rick Shadyac, CEO of ALSAC, the fundraising and awareness organization for St. Jude and the nation's second largest health care charity. "I look forward to working in partnership with him as we continue to advance St. Jude's mission as the global leader in the treatment and research of pediatric cancer and other deadly diseases afflicting children."

"Having tried to attract Jim Downing to my own institutions over many years, I am well-positioned to congratulate St. Jude and to say with confidence that Jim has all the qualitiesintellectual and socialthat will guarantee St. Jude's sustained success as a center for cancer research and care," said Nobel laureate Harold Varmus, M.D., National Cancer Institute director

"Jim Downing is the perfect choice to guide St. Jude at this exciting time in cancer therapy, where science and medicine are so closely intertwined," said Charles Sawyers, M.D., Howard Hughes Medical Institute Investigator and Chairman of Human Oncology, Memorial Sloan-Kettering Cancer Center. "He has the right blend of laboratory and clinical expertise, plus a strong track record in building and leading effective teams to tackle big challenges. As a member of the St. Jude Scientific Advisory Board, I am looking forward to seeing them climb to new heights."

"Jim is an outstanding choice to lead St. Jude," said William G. Kaelin Jr., M.D., professor of Medicine, Howard Hughes Medical Institute Investigator, Dana-Farber Cancer Institute and Harvard Medical School. "He is widely admired in the scientific community as an innovator and thought leader in cancer genomics and cancer pathogenesis. During my tenure on the St. Jude Scientific Advisory Board, I witnessed firsthand Jim's remarkable grasp of the many interconnected activities at St. Jude that, collectively, make it the national treasure that it is today. He is a soft-spoken, humble person who commands respect because of his many scientific accomplishments coupled with his well-deserved reputation for fairness and sound judgment. I simply cannot think of a better person to lead St. Jude into the future."


Contact: Carrie Strehlau
St. Jude Children's Research Hospital

Related medicine news :

1. Vibrant Nutraceuticals Announces Launch of Vegan Childrens’ Probiotic, KidsLac
2. CHOC researchers identify technique to reduce childrens post-op pain after high-risk surgery
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. NIH awards $20 million over 5 years to train next generation of global health researchers
5. Researchers develop a new cell and animal model of inflammatory breast cancer
6. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
7. Sexually abused boys at risk for more unsafe sex: UBC research
8. Researchers Find Gene Mutations That May Be a Key to Autism
9. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
10. Researchers find evidence of banned antibiotics in poultry products
11. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
Post Your Comments:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: